Tebex Limited Filleted Accounts Cover |
Audited accounts | |||||||||
Company No. 08129184 | |||||||||
Tebex Limited Directors Report Registrar |
The Directors present their report and the accounts for the year ended 31 December 2024. | |||||||||
Principal activities | |||||||||
Directors | |||||||||
The Directors who served at any time during the year were as follows: | |||||||||
U. Marchand | |||||||||
L.J. McNeil | |||||||||
Auditors | |||||||||
The auditors, Gordon Levy Limited, will be proposed for appointment in accordance with Section 486 of the Companies Act 2006. | |||||||||
Signed on behalf of the board | |||||||||
U. Marchand | |||||||||
Director | |||||||||
21 September 2025 | |||||||||
Tebex Limited Balance Sheet Registrar |
at | ||||||||||
Company No. | Notes | 2024 | 2023 | |||||||
Restated | ||||||||||
£ | £ | |||||||||
Fixed assets | ||||||||||
Tangible assets | 5 | |||||||||
Investments | 6 | |||||||||
Current assets | ||||||||||
Debtors | 7 | |||||||||
Cash at bank and in hand | ||||||||||
Creditors: Amount falling due within one year | 8 | ( | ( | |||||||
Net current assets | ||||||||||
Total assets less current liabilities | ||||||||||
Net assets | ||||||||||
Capital and reserves | ||||||||||
Called up share capital | ||||||||||
Capital redemption reserve | 11 | |||||||||
Profit and loss account | 11 | |||||||||
Total equity | ||||||||||
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account. | ||||||||||
Approved by the board on 21 September 2025 and signed on its behalf by: | ||||||||||
U. Marchand | ||||||||||
Director | ||||||||||
21 September 2025 | ||||||||||
Tebex Limited Notes to the Accounts Registrar |
for the year ended 31 December 2024 | ||||||||||||||
1 | General information | |||||||||||||
Tebex Limited is a private company limited by shares and incorporated in England and Wales. | ||||||||||||||
The company's registered number is: 08129184 | ||||||||||||||
The address of the company's registered office is: | ||||||||||||||
Going concern | ||||||||||||||
2 | Accounting policies | |||||||||||||
Turnover | ||||||||||||||
Revenue from commissions and subscriptions are recognised when all revenue recognition criteria have been satisfied: persuasive evidence of an agreement exists, the delivery of the service has been rendered, the fees are fixed or determinable and collectability is probable. | ||||||||||||||
Intangible fixed assets | ||||||||||||||
Tangible fixed assets and depreciation | ||||||||||||||
At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss. | ||||||||||||||
Plant and machinery | ||||||||||||||
Research and development costs | ||||||||||||||
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years. | ||||||||||||||
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only. | ||||||||||||||
Taxation | ||||||||||||||
Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Current or deferred tax for the year is recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively. | ||||||||||||||
Investments | ||||||||||||||
Trade and other debtors | ||||||||||||||
Trade and other creditors | ||||||||||||||
Foreign currencies | ||||||||||||||
Judgements and key sources of estimation uncertainty | ||||||||||||||
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors including expectations of future events that are believed to be reasonable under the circumstances. | ||||||||||||||
Financial instruments | ||||||||||||||
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable. | ||||||||||||||
Cash and cash equivalents | ||||||||||||||
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. | ||||||||||||||
Leases | ||||||||||||||
Assets held under finance leases, which are leases where substantially all the risks and rewards of ownership of the assets have passed to the company, are capitalised in the balance sheet as tangible fixed assets and are depreciated over their useful lives. The capital elements of future obligations under the leases are included as liabilities in the balance sheet. The interest element of the rental obligation is charged to the profit and loss account over the period of the lease and represents a constant proportion of the balance of capital repayments outstanding. | ||||||||||||||
Assets held under hire purchase agreements are capitalised as tangible fixed assets and are depreciated over their useful lives. The capital element of future finance payments is included within creditors. Finance charges are allocated to accounting periods over the length of the contract. | ||||||||||||||
Financial assets | ||||||||||||||
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is identified, an impairment loss is recognised in profit or loss. | ||||||||||||||
For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. | ||||||||||||||
For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and its recoverable amount, which is an estimate of the amount that the company would receive for the asset if it were to be sold at the reporting date. | ||||||||||||||
Defined contribution pensions | ||||||||||||||
The contributions are recognised as expenses when they fall due. Amounts not paid are shown in accruals in the balance sheet. The assets of the plan are held separately from the company in independently administered funds. | ||||||||||||||
Share based payments | ||||||||||||||
Share-based payment arrangements in which the entity receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions, regardless of how the equity instruments are obtained by the entity. | ||||||||||||||
The grant date fair value of share-based payments awards granted to employees is recognised as an employee expense, with a corresponding increase in equity, over the period in which the employees become unconditionally entitled to the awards. The fair value of the awards granted is measured based on using an option valuation model, taking into account the terms and conditions upon which the awards were granted. The amount recognised as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognised as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Where the terms and conditions of options are modified before they vest, the increase in the fair value of options, measured immediately before and after the modification, is also charged to the Profit and Loss account over the remaining vesting period. | ||||||||||||||
3 | Prior year adjustment | |||||||||||||
The comparative figures have been changed from the figures previously shown in the financial statements for the year ended 31 December 2023. | ||||||||||||||
This has resulted in a reclassification from trade debtors to other debtors, a decrease of £483,425 in costs of sales, an increase of £498,377 in administrative expenses and an increase in intercompany creditors of £14,952. | ||||||||||||||
4 | Employees | |||||||||||||
2024 | 2023 | |||||||||||||
Number | Number | |||||||||||||
The average monthly number of employees (including directors) during the year was: | ||||||||||||||
5 | Tangible fixed assets | |||||||||||||
Plant and machinery | Total | |||||||||||||
£ | £ | |||||||||||||
Cost or revaluation | ||||||||||||||
At 1 January 2024 | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Depreciation | ||||||||||||||
At 1 January 2024 | ||||||||||||||
Charge for the year | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Net book values | ||||||||||||||
At 31 December 2024 | ||||||||||||||
At 31 December 2023 | 37,722 | |||||||||||||
6 | Investments | |||||||||||||
Investment in Subsidiaries | Total | |||||||||||||
£ | £ | |||||||||||||
Cost or valuation | ||||||||||||||
At 1 January 2024 | ||||||||||||||
At 31 December 2024 | ||||||||||||||
Provisions/Impairment | ||||||||||||||
Net book values | ||||||||||||||
At 31 December 2024 | ||||||||||||||
At 31 December 2023 | ||||||||||||||
The investment in subsidiary company represents the whole share capital of Tebex Inc, a trading company registered in the USA. | ||||||||||||||
7 | Debtors | |||||||||||||
2024 | 2023 | |||||||||||||
Restated | ||||||||||||||
£ | £ | |||||||||||||
Amounts owed by group undertakings | ||||||||||||||
Deferred tax asset | ||||||||||||||
Loans to directors | ||||||||||||||
Other debtors | ||||||||||||||
Prepayments and accrued income | ||||||||||||||
Note 3 contains the details of a prior year adjustment which impacts on this disclosure note. | ||||||||||||||
8 | Creditors: | |||||||||||||
amounts falling due within one year | ||||||||||||||
2024 | 2023 | |||||||||||||
Restated | ||||||||||||||
£ | £ | |||||||||||||
Trade creditors | ||||||||||||||
Amounts owed to group undertakings | ||||||||||||||
Taxes and social security | ||||||||||||||
Loans from directors | ||||||||||||||
Other creditors | ||||||||||||||
Accruals and deferred income | ||||||||||||||
Note 3 contains the details of a prior year adjustment which impacts on this disclosure note. | ||||||||||||||
9 | Share based payments | |||||||||||||
The company operates an employee share option plan, 108200 options have been granted in 2024 (2023: 115900) for shares in the ultimate parent company. | ||||||||||||||
Details of the share options outstanding during the year are as follows, presented in USD: | ||||||||||||||
Weighted average exercise price | Number | Weighted average exercise price | Number | |||||||||||
2024 | 2024 | 2023 | 2023 | |||||||||||
Outstanding as at beginning of year | 1.93 | 201,594 | 1.20 | 93,751 | ||||||||||
Granted during the year | 1.50 | 108,200 | 1.93 | 115,900 | ||||||||||
Cancelled during the year | 1.93 | (40,882) | 1.20 | (8,057) | ||||||||||
Outstanding as at the end of the year | ||||||||||||||
1.50 | 268,912 | 1.93 | 201,594 | |||||||||||
2024 | 2023 | |||||||||||||
Black- scholes | Black- scholes | |||||||||||||
Share price | 2.83 | 2.58 | ||||||||||||
Exercise price | 1.50 | 1.20 | ||||||||||||
Contractual life (years) | 6.03 | 5.73 | ||||||||||||
Expected volatility | 51.61% | 50.00% | ||||||||||||
Risk-free interest rate | 4.11% | 4.19% | ||||||||||||
2024 | 2023 | |||||||||||||
£ | £ | |||||||||||||
Equity-settled schemes | (184,620) | (90,911) | ||||||||||||
10 | Share Capital | |||||||||||||
The total of ordinary shares was 10,881 ordinary shares valued at £0.01 each (2023: Total of ordinary shares was 10,881 of £0.01 each) | ||||||||||||||
11 | Reserves | |||||||||||||
Capital redemption reserve | Total other reserves | |||||||||||||
£ | £ | |||||||||||||
Transfers | ||||||||||||||
At 31 December 2023 and 1 January 2024 | ||||||||||||||
Transfers | ||||||||||||||
At 31 December 2024 | ||||||||||||||
12 | Dividends | |||||||||||||
2024 | 2023 | |||||||||||||
£ | £ | |||||||||||||
Dividends for the period: | ||||||||||||||
Dividends paid in the period | 3,951,026 | 4,640,590 | ||||||||||||
4,640,590 | ||||||||||||||
Dividends by type: | ||||||||||||||
Equity dividends | ||||||||||||||
3,951,026 | 4,640,590 | |||||||||||||
13 | Related party transactions | |||||||||||||
Control: | ||||||||||||||
The immediate parent company is Overwolf UK Ltd a company incorporated and registered in England & Wales. The company's ultimate parent undertaking and the largest group in which the company's results are consolidated is Overwolf Ltd, a company incorporated and registered in Israel. | ||||||||||||||
Copies of Overwolf Ltd's consolidated accounts maybe obtained from its registered office at 40 Tuval Street, Ramat Gan, 5252247, Israel. | ||||||||||||||
Transactions: | ||||||||||||||
The company is exempt from disclosing transactions with related parties that are wholly owned within the same group in accordance with FRS 102 Section 33. | ||||||||||||||
14 | Audit of the accounts | |||||||||||||
Unqualified | ||||||||||||||
The auditors were: Gordon Levy Limited | ||||||||||||||
The senior statutory auditor was: Gordon Levy BA, FCA | ||||||||||||||